MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Cantrixil

CAS No. : 2135511-22-5

MCE 站：Cantrixil

产品活性：Cantrixil (TRX-E-002-1) 是 TRX-E-002 的活性对映异构体，是第二代超级苯并吡喃 (SBP) 化合物。Cantrixil 增加磷酸化 c-Jun 水平，导致卵巢癌细胞中半胱天冬酶介导的细胞凋亡。Cantrixil 对广泛的癌症表型具有有效的泛抗癌活性。

研究领域：Apoptosis

作用靶点：Apoptosis

In Vitro: TRX-E-002-1 shows broad cytotoxic activity against ovarian, prostate ａnd lung cancer cells, with IC₅₀ values ≤0.1 μM (SK-OV-3, JAM, OVCAR-3 cells: IC₅₀=0.023-0.065 μM; DU145, PC3; C4-2B cells: IC₅₀=0.014-0.096 μM; A549 cells: IC₅₀=0.058 μM). Activity in pancreatic ａnd colorectal cancer cells ａnd glioblastoma cells are more variable.
Cantrixil (0.2 μM; 2-24 hours) shows higher levels of phosphorylated c-Jun (p-c-Jun) ａnd lower levels of phosphorylated-ERK (p-ERK).
Cantrixil (2.45 μM; 2-24 hours) induces a significant increase in both caspase-3/7 ａnd caspase-9 activity at 16 ａnd 24 hours.
TRX-E-002-1 inhibits multiple cytochrome P450 drug-metabolizing enzymes, including CYP2C9, CYP2C8, CYP2C19, CYP2B6, CYP3A4, CYP2D6, CYP2A6 ａnd CYP1A2. IC₅₀ values ranges from 1.5 to 75 μM (612-30,600 ng/mL).

In Vivo: TRX-E-002-1 (100 mg/kg/day; IP; for 13-14 days) significantly inhibits tumour growth in disseminated ovarian cancer mouse model.
TRX-E-002-1 (100 mg/kg/day; IP; for 4 weeks) inhibits tumour growth ａnd reduced terminal tumour burden by 77% in the recurrent ovarian cancer mouse model.
TRX-E-002-1 (100 mg/kg/day; IP; for 18 days) significantly reduces terminal pancreatic tumour burden in a mouse model of pancreatic cancer (human Panc-1 pancreatic tumour cells implanted orthotopically into female NOD-SCID mice).
TRX-E-002-1 (100 mg/kg; IP) has a T_1/2 of 2.5 hours, a C_max of 8355 ng/mL ａnd an AUC_0-∞ of 40600 ng•h/mL.

相关产品：MG-132  |  LY294002  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Y-27632 dihydrochloride  |  Paclitaxel  |  Acetylcysteine  |  Angiotensin II human  |  SP600125  |  Sorafenib  |  Staurosporine  |  5-Fluorouracil  |  Bortezomib  |  Trametinib  |  Tamoxifen  |  2-Deoxy-D-glucose  |  Gemcitabine  |  MK-2206 dihydrochloride  |  Temozolomide  |  Verteporfin  |  Actinomycin D  |  Decitabine  |  Etoposide  |  BAY 11-7082  |  Pexidartinib  |  Mitomycin C  |  CCCP  |  DAPT  |  Ruxolitinib

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。